Antagonisme < Antagoniste < Antagoniste analgésique narcotique

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 40.
[0-20] [0 - 20][0 - 40][20-40]

Ident.	Authors (with country if any)	Title
002406 (2003)	Rajesh Pahwa [États-Unis] ; Kelly E. Lyons [États-Unis]	Mirtazapine in essential tremor: A double-blind, placebo-controlled pilot study
002449 (2003)	William G. Ondo [États-Unis] ; Christine Hunter [États-Unis]	Flumazenil, a GABA antagonist, may improve features of Parkinson's Disease
002450 (2003)	Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni]	Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
002556 (2002)	Ergun Y. Uc [États-Unis] ; Gerald A. Dienel [États-Unis] ; Nancy F. Cruz [États-Unis] ; Sami I. Harik [États-Unis]	β-Adrenergics enhance brain extraction of levodopa
002605 (2002)	Guy Arnold [Allemagne] ; Klaus Tatsch [Allemagne] ; Eduardo Kraft [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Johannes Schwarz [Allemagne]	Steele-Richardson-Olszewski syndrome: Reduction of dopamine D2 receptor binding relates to the severity of midbrain atrophy in vivo: 123IBZM SPECT and MRI study
002621 (2002)	Johannes Schiefer [Allemagne] ; G. Bernhard Landwehrmeyer [Allemagne] ; Hans-Gerd Lüesse [Allemagne] ; Arne Sprünken [Allemagne] ; Christiane Puls [Allemagne] ; Anna Milkereit [Allemagne] ; Eva Milkereit [Allemagne] ; Christoph M. Kosinski [Allemagne]	Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease
002790 (2002)		Drugs to treat autonomic dysfunction in Parkinson's disease
002834 (2002)	Joanne E. Nash [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni]	Characterisation of striatal NMDA receptors involved in the generation of Parkinsonian symptoms: Intrastriatal microinjection studies in the 6-OHDA-lesioned rat
002859 (2002)		Anticholinergic therapies in the treatment of Parkinson's disease
002863 (2002)		Amantadine and other antiglutamate agents
002952 (2001)	Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni]	Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct : Evidence from the effects of the Alpha2 adrenoceptor antagonist idazoxan
002980 (2001)	Olivier Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France]	Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease
002A96 (2000)	Hasmet A. Hanagasi [Turquie] ; Gülüstü Kaptanoglu [Turquie] ; Hüseyin A. Sahin [Turquie] ; Murat Emre [Turquie]	The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa
002B22 (2000)	N. A. Leopold [États-Unis]	Risperidone treatment of drug-related psychosis in patients with Parkinsonism
002B40 (2000)	C. G. Goetz [États-Unis] ; T. Q. Vu ; P. M. Carvey ; S. Leurgans	Posthypoxic myoclonus in the rat : Natural history, stability, and serotonergic influences
002B94 (2000)	A. J. Manson [Royaume-Uni] ; E. Iakovidou [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]	Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease
002C95 (1999)	J. Wissel [Autriche] ; J. Müller [Autriche] ; G. Ebersbach [Autriche] ; Werner Poewe [Autriche]	Trick maneuvers in cervical dystonia : Investigation of movement- and touch-related changes in polymyographic activity
002D01 (1999)	B. Henry [Royaume-Uni] ; S. H. Fox [Royaume-Uni] ; D. Peggs [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Royaume-Uni]	The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-Parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease
002D09 (1999)	S. Spieker [Allemagne] ; P.-A. Löschmann [Allemagne] ; T. Klockgether [Allemagne]	The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations
002D29 (1999)	H. D. Rosas [États-Unis] ; W. J. Koroshetz [États-Unis] ; B. G. Jenkins [États-Unis] ; Y. I. Chen [États-Unis] ; D. L. Hayden [États-Unis] ; M. F. Beal [États-Unis] ; M. E. Cudkowicz [États-Unis]	Riluzole therapy in Huntington's Disease (HD)
002D32 (1999)	A. Schrag [Royaume-Uni] ; L. Schelosky [Allemagne] ; U. Scholz [Allemagne] ; Werner Poewe [Autriche]	Reduction of parkinsonian signs in patients with parkinson's disease by dopaminergic versus anticholinergic single-dose challenges

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/PascalFr.i -k "Antagoniste" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/PascalFr.i  \
                -Sk "Antagoniste" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    indexItem
   |index=    PascalFr.i
   |clé=    Antagoniste
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024